Premium
Teicoplanin‐dependent antibodies: detection and characterization
Author(s) -
Garner Stephen F.,
Campbell Kate,
Smith Graham,
Hurd Colin,
Davidson Simon J.,
Treacy Marilyn,
Burman John F.,
Kroll Hartmut,
Ouwehand Willem H.
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2005.05430.x
Subject(s) - teicoplanin , platelet , glycopeptide , antibody , chinese hamster ovary cell , medicine , flow cytometry , thrombocytopenic purpura , immunology , antibiotics , microbiology and biotechnology , biology , bacteria , vancomycin , staphylococcus aureus , receptor , genetics
Summary There are only a few reports of thrombocytopenia associated with clinical doses of teicoplanin, a glycopeptide antibiotic used against Gram‐positive bacteria. We investigated 39 patients receiving teicoplanin; 31 were thrombocytopenic with platelet counts between 1–105 × 10 9 /l and 8 were not thrombocytopenic. We identified 14 thrombocytopenic cases (45%) and two (25%) non‐thrombocytopenic cases with IgG teicoplanin‐dependent platelet‐reactive antibodies. Use of glycoprotein (GP) capture enzyme‐linked immunosorbent assay with platelets and GPIIb/IIIa transfected Chinese Hamster Ovary cells as well as flow cytometry with GP‐deficient platelets indicated that the GPIIb/IIIa complex is a major target antigen of these antibodies.